OMJJARA GlaxoSmithKline Australia Pty Ltd
Product name
OMJJARA
Accepted date
May-2024
Active ingredients
momelotinib dihydrochloride monohydrate
Proposed indication
For the treatment of disease-related splenomegaly.
Application type
A (new medicine)
Publication date
May-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.